NLTX vs. INZY, AQST, RANI, CRMD, CTNM, VTYX, NATR, ME, ENTA, and XERS
Should you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Inozyme Pharma (INZY), Aquestive Therapeutics (AQST), Rani Therapeutics (RANI), CorMedix (CRMD), Contineum Therapeutics (CTNM), Ventyx Biosciences (VTYX), Nature's Sunshine Products (NATR), 23andMe (ME), Enanta Pharmaceuticals (ENTA), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical preparations" industry.
Neoleukin Therapeutics (NASDAQ:NLTX) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.
52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 11.9% of Inozyme Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Neoleukin Therapeutics' return on equity of -37.22% beat Inozyme Pharma's return on equity.
Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Inozyme Pharma had 16 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 16 mentions for Inozyme Pharma and 0 mentions for Neoleukin Therapeutics. Inozyme Pharma's average media sentiment score of 0.59 beat Neoleukin Therapeutics' score of 0.00 indicating that Inozyme Pharma is being referred to more favorably in the news media.
Inozyme Pharma has a consensus target price of $17.00, indicating a potential upside of 259.41%. Given Inozyme Pharma's higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than Neoleukin Therapeutics.
Neoleukin Therapeutics received 15 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 81.40% of users gave Inozyme Pharma an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.
Summary
Inozyme Pharma beats Neoleukin Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Neoleukin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neoleukin Therapeutics Competitors List
Related Companies and Tools
